CL2024002490A1 - Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa - Google Patents
Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasaInfo
- Publication number
- CL2024002490A1 CL2024002490A1 CL2024002490A CL2024002490A CL2024002490A1 CL 2024002490 A1 CL2024002490 A1 CL 2024002490A1 CL 2024002490 A CL2024002490 A CL 2024002490A CL 2024002490 A CL2024002490 A CL 2024002490A CL 2024002490 A1 CL2024002490 A1 CL 2024002490A1
- Authority
- CL
- Chile
- Prior art keywords
- salt
- crystalline form
- inhibitor compound
- dipeptidyl peptidase
- peptidase inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cooling Or The Like Of Semiconductors Or Solid State Devices (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210160862 | 2022-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002490A1 true CL2024002490A1 (es) | 2024-12-13 |
Family
ID=87764787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002490A CL2024002490A1 (es) | 2022-02-22 | 2024-08-20 | Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250188067A1 (https=) |
| EP (1) | EP4484414A4 (https=) |
| JP (1) | JP2025508792A (https=) |
| KR (1) | KR20240153351A (https=) |
| CN (1) | CN118660873A (https=) |
| AU (1) | AU2023225835A1 (https=) |
| CA (1) | CA3243683A1 (https=) |
| CL (1) | CL2024002490A1 (https=) |
| IL (1) | IL314852A (https=) |
| MX (1) | MX2024010180A (https=) |
| TW (1) | TW202342466A (https=) |
| WO (1) | WO2023160542A1 (https=) |
| ZA (1) | ZA202407225B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL314855A (en) * | 2022-02-22 | 2024-10-01 | Haisco Pharmaceuticals Pte Ltd | Preparation method of nitrogen-containing heterocyclic compound |
| JP2026503035A (ja) | 2023-01-06 | 2026-01-27 | インスメッド インコーポレイテッド | 新規な可逆性ｄｐｐ１阻害剤及びその用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7902181B2 (en) * | 2007-12-12 | 2011-03-08 | Astrazeneca Ab | Compounds 010 |
| NO2699580T3 (https=) * | 2014-01-24 | 2018-02-24 | ||
| CN115996923B (zh) * | 2020-08-26 | 2025-07-18 | 海思科医药集团股份有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| CN114106005B (zh) * | 2020-08-26 | 2025-08-01 | 西藏海思科制药有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| CN114591315A (zh) * | 2020-12-04 | 2022-06-07 | 瑞石生物医药有限公司 | 一种组织蛋白酶c小分子抑制剂 |
| US20240150335A1 (en) * | 2021-02-05 | 2024-05-09 | Medshine Discovery Inc. | Fused ring derivatives containing 1,4-oxazepane |
-
2023
- 2023-02-21 JP JP2024549554A patent/JP2025508792A/ja active Pending
- 2023-02-21 KR KR1020247031067A patent/KR20240153351A/ko active Pending
- 2023-02-21 US US18/840,826 patent/US20250188067A1/en active Pending
- 2023-02-21 MX MX2024010180A patent/MX2024010180A/es unknown
- 2023-02-21 AU AU2023225835A patent/AU2023225835A1/en active Pending
- 2023-02-21 CA CA3243683A patent/CA3243683A1/en active Pending
- 2023-02-21 EP EP23759167.2A patent/EP4484414A4/en active Pending
- 2023-02-21 WO PCT/CN2023/077409 patent/WO2023160542A1/zh not_active Ceased
- 2023-02-21 IL IL314852A patent/IL314852A/en unknown
- 2023-02-21 CN CN202380015239.3A patent/CN118660873A/zh active Pending
- 2023-02-22 TW TW112106411A patent/TW202342466A/zh unknown
-
2024
- 2024-08-20 CL CL2024002490A patent/CL2024002490A1/es unknown
- 2024-09-20 ZA ZA2024/07225A patent/ZA202407225B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4484414A4 (en) | 2026-01-28 |
| WO2023160542A1 (zh) | 2023-08-31 |
| AU2023225835A1 (en) | 2024-10-03 |
| ZA202407225B (en) | 2025-12-17 |
| CN118660873A (zh) | 2024-09-17 |
| EP4484414A1 (en) | 2025-01-01 |
| MX2024010180A (es) | 2024-08-27 |
| JP2025508792A (ja) | 2025-04-10 |
| TW202342466A (zh) | 2023-11-01 |
| IL314852A (en) | 2024-10-01 |
| US20250188067A1 (en) | 2025-06-12 |
| KR20240153351A (ko) | 2024-10-22 |
| CA3243683A1 (en) | 2025-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002490A1 (es) | Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa | |
| MX2020012965A (es) | Combinacion, composicion y preparacion de compuesto farmaceutico que comprende activador de glucocinasa e inhibidor de dpp-iv, metodo de preparacion y uso del mismo. | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| MX2019008853A (es) | Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2). | |
| EP4516353A3 (en) | Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide | |
| CO6220933A2 (es) | Formulaciones de dosis unitaria y metdods para el tratamiento de la trombosis con un inhibidor oral del facror xa | |
| SA521421645B1 (ar) | بيرولينات إندماجية تعمل كمثبطات بروتياز نوعي لأوبيكويتين 30 | |
| CO2021009083A2 (es) | Compuestos y su uso para el tratamiento de la deficiencia de α1-antitripsina | |
| MX2020013116A (es) | Sales y cristales novedosos. | |
| PE20220017A1 (es) | Inhibidores del kcnt1 y metodos de uso | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| ECSP088339A (es) | Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| CO6220969A2 (es) | Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo | |
| CL2021001629A1 (es) | Compuestos de halo-alilamina y uso de los mismos | |
| UY38592A (es) | Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada, proceso para su preparación y composiciones farmacéuticas que las contienen | |
| RU2017117559A (ru) | Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение | |
| MX2022001759A (es) | Composicion farmaceutica oral que contiene compuesto heterociclico. | |
| MX390507B (es) | Compuestos de amida y su uso. | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| UY38006A (es) | Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones | |
| MX2017009853A (es) | Prevencion o tratamiento de enfermedades urinarias o gotosas. | |
| CO2024014215A2 (es) | Formulaciones de inhibidor de tyk2 y métodos para elaborarlas |